Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Single-Arm Study of Nivolumab in Relapsed or Refractory DLBCL After ASCT Failure or ≥2 Prior Regimens
2013-003621-28Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), transformed lymphoma and non-Hodgkin lymphoma (NHL), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Dec 2013; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)transformed lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2013-003621-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003621-28.